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Composite endpoints are a popular outcome in controlled studies. However, the required
sample size is not easily obtained due to the assortment of outcomes, correlations between
them and the way in which the composite is constructed. Data simulations are required. A
macro is developed that enables sample size and power estimation.
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Introduction
Nonparametric composite endpoints which combine individual study outcomes into
a single univariate measure are becoming an increasingly popular primary endpoint
in controlled studies; a recent survey showed approximately 50% of studies adopted
a composite (Ferreira-Gonzalez et al., 2007). They may be favored due to the
increase in power offered over the analysis of individual outcomes, or to calibrate
potentially optimistic surrogate endpoints with clinical outcomes that show lower
event rates, and to obtain an overall effect of the treatment or intervention.
Composites of the type described here were considered in various fields of
research such as psychology (Pedersen, van Domburg, & Larsen, 2004), HIV
(Finkelstein & Schoenfeld, 1999), oncology (Buyse, 2010), brain injury (Temkin
et al., 2007), limb ischemia (Subherwal et al., 2012), and heart failure (Allen &
Spertus, 2013). However, a review of endpoints in acute heart failure noted that the
varied use of such endpoints “remains a major potential barrier to progress in the
field” (Allen, Hernandez, O'Connor, & Felker, 2009, p. 1), thus some guidance and
consistency in use is needed.
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Several composites have been proposed and preference will depend on the
purpose of the study. Sun, Davison, Cotter, Pencina, and Koch (2012) compared an
eclectic mix of composites based on power estimates. But few papers have
emphasized the limitations of composite endpoints (Chi, 2005; Neaton, Gray,
Zuckerman, & Konstam, 2005) or described power calculations (Matsouaka &
Betensky, 2015; Subherwal et al., 2012) and thorough power assessment that takes
correlations among outcomes into account by using simulations may be lacking.
Programs for sample size estimation are not readily available to the researcher
when designing a study that employs a composite of novel endpoints. Because
construction of the composite is to an extent ad hoc (e.g. how to weight or prioritize
outcomes, the number of outcomes etc.) the standard equations for sample size
estimation do not apply. This is especially the case for those composite endpoints
which are unrestricted in the number and type of outcomes they are composed of.
Such composites are the focus of this paper.
The objective here is to describe SAS/IML macros developed which enable
the derivation of two popular but quite different composite endpoints and employ
data simulations to obtain power and sample size estimates and hence inform study
design. With the use of the macros it becomes an easy matter to evaluate the
sensitivity of power to changes in the assumptions made, e.g. about the size of the
treatment effect on outcomes and the correlations among outcomes. This code,
available for download, is used to plan a study in acute heart failure which is used
to illustrate the use of the macros and provide example output. SAS/IML macros
described in the following section are available to download here:
digitalcommons.wayne.edu/jmasm/vol16/iss2/11/. They were developed using
SAS 9.4 and SAS procs. The macros which derive the composite endpoints may
also be used independently of the simulations macro i.e. to derive and analyze the
composite endpoints at study completion.

Methodology
The composite endpoints of interest are the global rank (Felker & Maisel, 2010)
and the average Z-score (Sun et al., 2012). They were used, for example, in the
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study which
compared Liraglutide and placebo groups using a global rank composite
comprising mortality, hospital readmission and time-averaged proportional change
in N-terminal pro-B-type natriuretic peptide (NTproBNP) level (Margulies et al.,
2014). They were also used in the biased ligand of the angiotensin receptor study
in acute heart failure (BLAST-AHF) study which used an average Z-score to
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compare three dose groups and a placebo in acute patients with heart failure (Felker
et al., 2016).
The global rank assigns each patient a rank according to their responses across
a number of outcomes. A rank of 1 is allocated to the patient with the most severe
response (an early death for example) and a rank of n (where n is the sample size)
is allocated to the patient with the most favorable response. This is achieved by
arranging the relevant outcomes in a meaningful way, for example with the most
definitive (e.g. mortality) at the top and perhaps a surrogate endpoint at the bottom.
If the patient dies they are ranked based on their survival time. If the patient does
not die then they may be ranked according to their response on the next outcome in
the hierarchy; if they do not fail on that outcome either, then we move to the next
outcome, and so forth down the hierarchy of outcomes until the patient receives
their rank.
The average Z-score, on the other hand, converts the response on each
outcome to a Z-score before combining these scores by taking the average (Z-scores
are obtained by subtracting the overall mean and dividing by the corresponding
standard deviation). Before taking the average, the Z-scores for the different
outcomes must be aligned so that e.g. a positive Z-score represents a beneficial
outcome. Thus, the global rank prioritizes outcomes according to a hierarchy and
thus weights them, while the average Z-score does not. Analysis for both
composites is by the Wilcoxon rank sum test. The average Z-score, at least with
regards power, seems superior (Sun et al., 2012).
The null hypothesis for the rank based composites is that the distribution of
ranks are equal for the treatment groups and rejection of this hypothesis implies
that the ranks are higher/lower for one of the treatments. Each composite produces
a score or rank per patient that summarizes their response to treatment (in the case
of the global rank all outcome data are not necessarily taken into account to
determine the patient’s score). These composites were chosen because their
differences imply they will be apt or favored according to the circumstances or
researcher, and comparable alternatives are scarce for the situation where various
types of outcomes are to be combined.
Composites amenable to this situation must be unrestricted with regard to the
number of outcomes they are derived from and therefore provide a broad summary
of efficacy. These composites may combine outcomes of varying types, e.g.
dichotomous, survival, log normal etc. Their nature implies difficulties not relevant
for other composites, e.g. data simulations are required for the estimation of power
and this is not straightforward when the outcomes must show certain correlations,
i.e. iterations are needed. Our aim was to develop SAS macros flexible enough to
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allow power estimation for the global rank and average Z-score which incorporate
any number of outcomes of any type and in any order (as required by the
hierarchical global rank), i.e. this is where SAS macros would prove most useful
because other composites are easily coded or less open to ad hoc construction.
Data Simulations (%simul_data)
Assumed treatment differences for each outcome are input into the SAS/IML macro
(%simul_data) which are converted to normal variates e.g. log(odds) for
dichotomous outcomes, log(hazard) for survival endpoints etc. (using e.g. the delta
method for the variance). Random samples of the normal variates are then
generated from a multivariate normal distribution using proc iml and the
randnormal function before being converted to the specified outcomes, e.g.
exponential survival times are generated by



log  u 
hazard

(1)

where u is from the standard uniform distribution (Austin, 2012) and lognormal
outcomes are converted to percentage change from baseline, i.e. 100 × (exp(x) – 1).
Correlations between outcomes are obtained via iteration (%iterat_simul)
because the covariance specified for the normal variates using the randnormal
function will not ultimately hold among the outcome variables of mixed type. To
ensure the correlations between outcomes are those specified by the user,
correlations among the normal variates are adjusted on subsequent iterations in
order that they converge to the desired values within a certain precision specified
by the user; iterations stop when the desired accuracy is achieved (the maximum
absolute difference between desired and actual correlations) or the maximum
number of iterations is reached. Correlations are determined using Pearson’s
correlation coefficient from proc corr (including binary outcomes because Pearson
produces the same correlation as the apt biserial point correlation). During iteration,
correlation matrices that are not positive definite are identified and the nearest
correlation matrix is determined using Higham’s method as per the NearestCorr
function described by Wicklin (2012). Multiple sources may inform what values to
assume for the correlations (see the illustrative example below).
The resulting dataset includes two sets of variables for the nominal ‘active’
and ‘control’ groups based on the treatment differences specified for each outcome,
with the number of random samples and the size of the samples also dictated by the
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user; it can easily be verified that the resulting outcomes have the properties
specified, e.g. mean response, etc. The run time for convergence and the accuracy
are outputted to a separate dataset containing the correlation matrices produced at
each iteration.
Global Rank (%derive_GR)
As described above, the global rank is a hierarchical composite meaning that the
outcomes are arranged according to importance, i.e. hard endpoints with low event
rates such as mortality are at the top with surrogate endpoints with higher responses
typically at the bottom. Patients proceed down the hierarchy until they fail on an
outcome according to some criterion. A decision rule employing criteria for failure
is not necessary for a global rank composite, but we follow the approach of Felker
and Maisel (2010) here; ‘global rank’ is a generic term and various specifications
could fall under this label (Califf, Harrelson-Woodlief, & Topol, 1990; Finkelstein
& Schoenfeld, 1999; Lachin, 1999; Margulies et al., 2014; Pocock, Ariti, Collier,
& Wang, 2012; Temkin et al., 2007). The intention is to assign every patient a rank
which reflects the severity of response.
Computationally, it is straightforward: patients are ranked according to their
response on an outcome if they are among the subset who fail on that outcome; the
patient retains the rank that corresponds to the outcome highest in the hierarchy.
There is a question of how to rank patients who do not fail on any outcomes, and
Felker and Maisel (2010) suggest ranking them on the outcome positioned last in
the hierarchy. There is a strong likelihood for tied ranks, e.g. a dichotomous
outcome will generate ties; note that handling of ties will depend on the software
used (Bergmann, Ludbrook, & Spooren, 2000).
A simple equation yielding arbitrary values that rank patients could be given
as follows:



 
rij  
si  min   ij  j     1  max  ij
j
j
n 
 

 G  r

iG

n

(2)

where n is the total sample size, G is the total number of outcomes, δij = 1 if patient
i failed on outcome j and 0 otherwise, and rij is the rank for patient i on outcome j
(rank 1 being the worst response and n being the best). Patients who fail on the last
outcome are included in the first term and those who do not are included in the
second term, although it is not necessary to define a criterion for failure on the last
outcome.
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The global rank composite is becoming increasingly popular in phase II
research; see the FIGHT study where the global rank was comprised of three
outcomes (Margulies et al., 2014). Its appeal is the simplicity of construction and
openness to input from researchers regarding prioritizing outcomes.
Average Z-Score (%derive_ZS)
The average Z-score, on the other hand, is computationally intensive and
statistically rigorous more so than intuitive. It is an extension of O’Brien’s wellknown rank sum composite (O’Brien, 1984) for outcomes of different types which
must be placed on par by first calculating Z-scores and then taking the average
across outcomes (we should also ensure that Z-scores are aligned so that, e.g.,
bigger scores represent better outcomes).
For survival endpoints this means first transforming to log-rank scores which
prolongs the run time of the program (we wrote a macro for this purpose
called %lrscores). The LR scores are calculated as
ˆ t 
1 
j

(3)

ˆ t 

j

(4)

ˆ  t   logSˆ  t 


(5)

for uncensored survival times, and

for censored survival times, where

is the cumulative hazard and Ŝ(t) may be obtained from proc lifetest (see e.g. Collett,
2003; Zink & Koch, 2012). The code accounts for censoring by truncating the
survival times generated (in order not to overestimate power, especially considering
the low event rates often expected for clinical outcomes such as mortality, thus
implying many tied Z-scores and reduced power). The log-rank scores thus
calculated can be validated by checking they sum to the log-rank test statistic (also
provided by proc lifetest).
Using the log rank scores, and for continuous and dichotomous variables too,
Z-scores are obtained by subtracting the mean across treatment groups and dividing
by the corresponding standard deviation; proc stdize is used for this purpose. For
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dichotomous outcomes we want to avoid division by zero for small samples with
low event rates (i.e. when all patients have the same response). This macro, as
for %derive_GR, uses Wilcoxon and proc npar1way (an output dataset includes a
p-value per random sample).

Results
Illustrative Power Calculation with Sample Output
When designing a clinical trial in acute heart failure we considered both the global
rank and the average Z-score as candidates for the primary endpoint. Given the
recruitment and funding feasibility of a pilot or phase II study and expected low
event rates for clinical outcomes, an increase in power obtained by combining
outcomes was obviously appealing. We deemed 80% power to be satisfactory and
planned to measure the following five outcomes: mortality at 30 days, heart failure
related hospital readmission at 30 days, worsening heart failure at day 7, dyspnea
by 5-day area-under-the curve visual analogue scale, and percent change in NTproBNP (N-terminal of the prohormone brain natriuretic peptide). It would not be
necessary to combine all five outcomes in the chosen composite. Instead the intent
is to evaluate how many outcomes would be needed to achieve sufficient power.
Thus, the data include two survival endpoints and single dichotomous,
continuous and log-normal endpoints. The ordering of outcomes as listed above
indicates the hierarchy employed for the global rank, i.e. mortality and hospital
readmission at the top and the surrogate biomarker NT-proBNP, which will
potentially show the greatest effect of treatment, at the bottom. The cut-offs
employed for the global rank are also implied: for example, 30 days for mortality
and hospital readmission and 7 days for worsening heart failure (as far as the code
is concerned, the cut-off for dichotomous outcomes is merely 1 indicating presence
of disease). These cut-offs and the order of outcomes for the global rank hierarchy
are specified in the %derive_GR macro and the outcome type (i.e. dichotomous,
survival etc.), and treatment differences are specified in the %simul_data macro.
Treatment responses on the control were based on available data, and modest
treatment effect sizes were assumed for the outcomes (2% for mortality,
readmission and worsening heart failure, 20% difference in change from baseline
NT-proBNP, and 500 for dyspnea visual analogue scale area under the curve).
Correlations between outcomes deemed plausible are shown in Table 1. These were
based on in-house and published data e.g. Sun et al. (2012, p. 742) noted that “there
is a lack of correlation between treatment effects for surrogate endpoints and those
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for symptom relief or outcome.” The correlation between dyspnea and worsening
heart failure (WHF) is high because the latter is derived based on the former (among
other data). Within the %iterat_simul macro, criterion=0.05, indicating that the
maximum allowable difference between the resulting correlations and the desired
correlations is 0.05. Initial working correlations are specified in %simul_data.
Table 1. Correlations assumed between component outcomes

Mortality
Readmission
WHF
Dyspnea
NTproBNP

Mortality
1.00
0.10
-0.06
0.05
0.00

Readmission
0.10
1.00
-0.03
0.00
0.00

WHF
-0.06
-0.03
1.00
-0.60
0.00

Dyspnea
0.05
0.00
-0.60
1.00
0.00

Figure 1. Power versus number of outcomes by composite endpoint
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NTproBNP
0.00
0.00
0.00
0.00
1.00
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With a composite endpoint, when contemplating power the question isn’t
merely: How many patients are needed?, but may also be: How many outcomes?,
with additional outcomes possibly providing additional power (it is not infrequently
the case that an outcome's priority is inversely proportional to its sensitivity, i.e.
clinical outcomes such as mortality with low event rates are favored before
sensitive biomarkers, thus power increases as outcomes are added). There is
incentive to limit the outcomes contributing to the composite: missing data become
more pervasive the more outcomes used, the interpretability of the composite may
become murky, and in terms of data cleaning and validation the outcomes relevant
for the primary endpoint ought to receive the most scrutiny which demands extra
effort. Thus, in the following SAS code we vary the sample size and the number of
outcomes to be incorporated in the composites, deriving for each patient their score
for the two composites and then conducting the Wilcoxon test (proc npar1way) to
compare the nominal treatment groups:
%do varyn = 100 %to 500 %by 100;
%do varyvar = 3 %to 5 %by 1;
%iterat_simul(n_=&varyn, numvar_=&varyvar, criterion=0.05, out=randsamp);
%derive_GR(indata=randsamp, outdata=globrnk);
%derive_ZS(indata=randsamp, outdata=zscores);
%end;
%end;

Using 1000 simulated samples the power is then estimated as the percentage
of samples yielding a p-value < 0.05. The results are summarized in Figure 1. We
can see that to achieve 80% power we need to make use of all five outcomes and
recruit 300 patients, if the average Z-score is adopted, or an additional 200 patients
for the global rank. We should inflate these numbers to account for potential
missing data, bearing in mind that the effect on power would be greater for the
average Z-score (if a patient is missing on a single outcome then the average is
incalculable and the patient falls out of the analysis, without imputation, which is
not the case for the global rank). The addition of a fifth outcome results in a steeper
increase in power for the average Z-score. It is obvious that the average Z-score is
preferable with regard to power, however some researchers may have a strong
preference for a global rank based statistic (Felker, Anstrom, & Rogers, 2008). The
higher power for the Z-score is expected because it does not prioritize clinical
outcomes with low event rates, as the global rank does, and by doing so using the
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global rank we dampen the chances of an optimistic result; Neaton et al. (2005)
discuss weighted versus unweighted composites.
With any sample size calculation it is important to examine how sensitive the
power estimates are to changes in the assumptions made e.g. regarding the size of
the treatment effect. The size of the treatment difference is varied on each outcome
(including more pessimistic values), then re-evaluated power for the various
scenarios. The results are summarized in Figure 2. In this way uncertainty in the
assumptions is reflected in the spread of the box plots and we may now question
whether 300 patients are sufficient, depending on our confidence in the anticipated
treatment effect. We likewise varied the correlations assumed between mortality
and the other outcomes, considering only plausible values, i.e. those with
magnitude 0 and 0.1; the results are summarized in Figure 3. In this case uncertainty
regarding the strength of correlations between outcomes has a less pronounced
effect on power estimates, which might imply that a high degree of convergence
(i.e. accuracy ~ 0.01) is not essential. Although we can only say that correlations

Figure 2. Power versus sample size when treatment effect size is varied on outcomes
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Figure 3. Power versus sample size when correlations between outcomes are varied

do not seem important in this case and cannot extrapolate to other potential
scenarios (the correlation between e.g. mortality and readmission is necessarily
limited given that patients who die have less opportunity to record hospital
readmissions; although simulated data should reflect this, i.e. a patient is censored
for hospital readmission after death). We could also easily change the order of
outcomes in the hierarchy and assess what effect this has on power for the global
rank, however the ordering is a clinical decision rather than a statistical one.
These plots can be time consuming to run because the number of scenarios
increases with the number of outcomes and sample sizes considered (for Figure 2
there are 5 × 25 passes through the do-loop, with larger sample sizes consuming
more time, owing especially to the derivation of log-rank scores). The above code
for Figure 1 completes reasonably quickly however with a single pass through
taking between 2.85 and 8.35 minutes (depending on the number of outcomes) for
a sample size of 100. The maximum number of iterations was set to 50, although
correlations often converge in less than 10 iterations, and in the absence of
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convergence, i.e. at 50 iterations, reasonable accuracy (~ 0.05) was always
achieved.

Conclusion
The code is limited to five outcomes. It could easily be extended to include an
increased number of outcomes although this may not be advisable. Increasing the
number of outcomes increases the possibility of opposing effects and this would
adversely affect power. Also, the cogency and clarity of the composite may be
weakened when disparate outcomes are combined. Five outcomes strikes the right
balance as a maximum. Also, macros for other composites could be developed: in
our study we considered a modification of Finkelstein and Shoenfeld (1999),
although this was not included here because the approach and resulting power is
similar to the global rank (it is a global rank method with a different decision rule)
and the handling of survival and non-survival endpoints is sufficiently different to
make generalizing code difficult, i.e. the flexibility of a general program has less
value. A clinical composite may also be considered (Massie et al., 2010), although
like the Finkelstein and Schoenfeld endpoint it is too ad hoc to make a general
program useful, and it is easily coded. A macro was included for the unmatched
win-ratio composite (derive_WR) at the web link above; see the supplementary
material to Pocock et al. (2012) although note the small error in the variance
equation which should sum U2 from 1 to N.
The code was validated in a number of ways including reproducing power
estimates for current trials such as FIGHT which uses a global rank of three
outcomes (Margulies et al., 2014) and BLAST using an average Z-score for five
outcomes (Felker et al., 2015), both of which used data simulations for sample size
estimation. The macros have also been used to evaluate these composites (Brown,
Anstrom, Felker, & Ezekowitz, 2016). It is not meant to be implied the construction
of a composite should be based entirely on statistical reasoning, e.g. the power
attained; first and foremost it will be guided by clinical reasoning (Senn, 1989).
When power estimates are based on a composite of multiple endpoints it implies
multiple assumptions about, e.g. event rates. It would be prudent to plan an interim,
blinded reassessment of power.
The SAS macros described allow the user to readily obtain power estimates
when designing a phase II trial based on an overall summary of efficacy, namely
the global rank and average Z-score. It is thus easy to compare the composites and
evaluate how sensitive power is to a change in their construction or assumptions
about the anticipated treatment effects and correlations between the outcomes (such
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uncertainty ought to be reflected in the power estimates). The order of the outcomes
may be changed in the hierarchical global rank, although the order of outcomes is
a clinical decision and should determine the power, rather than vice versa.
Appropriate design of clinical trials is aided by a strong statistical framework
accounting for assumptions, prior data, estimated treatment effect and our macro
assists in that key design step.
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